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Blood platelets are first aimed at ensuring primary hemostasis. Beyond this role, they have been acknowledged
as having functions in the maintenance of the vascular arborescence and, more recently, as being also innate
immune cells, devoted notably to the detection of danger signals, of which infectious ones. Platelets express
pathogen recognition receptors that can sense bacterial and viral moieties. Besides, several molecules that bind
epithelial or sub-endothelial molecules and, so forth, are involved in hemostasis, happen to be able to ligate
viral determinants, making platelets capable of either binding viruses or even to be infected by some of them.
Further, as platelets express both Fc-receptors for Ig and complement receptors, they also bind occasionally
virus-Ig or virus-Ig-complement immune complexes. Interplays of viruses with platelets are very complex and
viral infections often interfere with platelet number and functions. Through a few instances of viral infections,
the present review aims at presenting some of the most important interactions from pathophysiological and
clinical points of view, which are observed between human viruses and platelets.
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There is a large body of evidence that several types of
viral infections led to sometimes severe and even life-
threatening bleeding. In some of those infections, the
platelet count drops dramatically; however, the precise
mechanisms involved either in platelet destruction or
impairment are still largely unclear, as well as the rela-
tive pathology counterpart of platelets and vascular
endothelial cells. More largely, thrombocytopenia is
common during or after viral infections and several
mechanisms have been proposed to contribute to the
drop of platelet count, including platelet destruction me-
diated by platelet-associated immunoglobulin G (IgG) or
platelet–leukocyte aggregation, possibly leading to se-
questration by macrophages, sequestration of platelets in
the enlarged spleen, impaired production of thrombo-
poiesis, and direct effect of viruses on platelets.
Besides, albeit apparently infrequent though poorly
examined in depth, platelets may bind and internalize* Correspondence: ogarraud@ints.fr
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unless otherwise stated.infectious agents, with little clue on the outcome of the
agent and of the “infected” platelet. The presence of vi-
ruses in platelets and their capacity of entry within those
cells has been acknowledged for more than half a cen-
tenary: as early as of 1959, influenza viruses were forced
to enter platelets experimentally, offering beautiful elec-
tronic microscopic images [1]. Questions relative to this
situation have not been addressed then, perhaps because
platelets were not yet acknowledged as “cells” but as
debris. Viruses indeed find panoply of receptors that are
not specific but rather permissive (as cartooned in
Figure 1). FcγR bound viruses can also enter platelets as
those cells can ingest immune complexes [2]. However,
it is not yet clear whether platelets, by taking up viruses,
contribute to the transport and the dissemination of in-
fection in vivo or if, on the contrary, they help the host
organism to defend against infection. Platelet–virus in-
teractions may have an ambivalent role, depending on
the virus species and on the platelet and megakaryocyte
(MK) environment [3].
This mini-review aims at addressing the apparent
complex issue of mutual relationships between certain
viruses and platelets.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Platelet receptors acknowledged to bind viruses, along with their primary molecular targets. CLEC-2: C-type lectin-like type II transmembrane
receptor. CR-2: Complement Receptor type 2. CCR-1, CCR-3, CCR-4: C-C chemokine Receptor type 1, 3 and 4. CXCR-1, CXCR-2, CXCR-4: C-X-C
chemokine receptor type 1, 2 and 4. DC-SIGN: Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin. GP-VI: Glycoprotein VI.
PAR-1/PAR-4: Platelet Activating Receptor ¼.
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HIV-1 is a single positive-stranded RNA virus belonging
to the Retroviridae family, genus Lentivirus. It was
first visualized in 1990 in platelets and MKs of
experimentally-infected mice [4]. In 2002, Youssefian
et al. consistently identified HIV-1 in human MKs and
platelets [5]. Several studies have thus clearly indicated
that, during infection with HIV-1, there is a direct inter-
action between the virus, MKs and platelets; indeed,
intact HIV-1 particles enclosed in endocytic vesicles
were found to be sheltered from platelet secretory
products while, when located in the surface connected
canalicular system (SCCS), they were in contact with
platelet secreted proteins [6]. These observations indi-
cate that (1) platelets are able to endocytose HIV-1
virions; (2) HIV-1 can be enclosed within platelets,
sheltered from host immune system aggression and
transported by circulating platelets within the entire
human body; and (3) viruses can come into contact
with platelet-secreted alpha-granule contents leading
to their destruction. In platelets incubated with HIV-1,
characteristic endocytic vacuoles were identified close
to the plasma membrane, tightly surrounding 1 or 2
viral particles. Examination of platelets from a patient
with acquired immunodeficiency syndrome and high
viremia suggested that HIV-1 endocytosis may also
occur in vivo [5].
Regarding the receptors that favor HIV-1 entry in
MKs and platelets, it has been found that MKs express
the CD4 receptor for HIV-1 [7] as well as the co-
receptors CXCR1, 2, 4, and CCR3 [8]. CXCR4+ MKshave been shown to be able to transfer CXCR4 to
CXCR4 negative cells, rendering them capable of being
infected by HIV-1 [9]. Platelets do not, however, express
CD4 but only bear the HIV-1 co-receptors CXCR1, 2, 4
and CCR 1,3 and 4 [10-13]. Dendritic cell-specific
ICAM-grabbing non-integrin (DC-SIGN), a C-type lec-
tin receptor present on both macrophages and dendritic
cells, has also been identified on platelets [6], with the
capacity of binding HIV-1 on platelets [6,14]. Platelets
also express the C-type lectin-like receptor 2 (CLEC-2).
Further, a combination of DC-SIGN and CLEC-2 inhibi-
tors strongly reduced the association of HIV-1 with
platelets, indicating that these lectins are required for
efficient HIV-1 binding to platelets [14].
Besides its entry in platelets, HIV-1 can activate in-
fected as well as non-infected—neighboring—platelets.
Indeed, HIV-1 trans-activator of transcription protein
(Tat) directly interacts with platelets and induces platelet
activation resulting in platelet micro-particle (PMP) re-
lease. This activation by Tat requires the chemokine re-
ceptor CCR3 and β3-integrin expression on platelets, as
well as calcium flux. Tat-activated platelets secrete
CD154 (CD40L) [15,16]. In general, enhanced platelet
activation in HIV-1-infected patients seems a hallmark
of the infection progression, as it strongly correlates with
plasma viral load. Indeed, HIV-1 and platelet interac-
tions engage the natural platelet partner that is vascular
endothelium: levels of soluble endothelial activation
markers (sVCAM-1, sICAM-1, and von Willebrand fac-
tor) are elevated in HIV-1 infected patients, and this ele-
vation may be associated with a thrombotic state [7]. As
stated, HIV-1 infection potentiates the pro-inflammatory
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reported to synergize and contribute to inflammation
[17]. Soluble CD40L also promotes the formation of
complexes between inflammatory monocytes and acti-
vated platelets, which are detected by flow cytometry as
monocytes::platelet doublets, which are positive for both
CD14 and CD61 [18]. On the contrary, platelets can also
secrete CXCL4/PF4 that is supposed to inhibit HIV-1 in-
fection of T cells [19,20]; this exemplifies the complex
relationship and interactions of platelets and viruses (for
instance HIV1). This (PF4) platelet-associated chemo-
kine indeed blocks HIV-1 entry and neutralizes HIV-1
activity, that suggests a role for platelets in the defense
against HIV-1 infection. However, platelet-derived PF4
facilitates HIV-1 replication in human macrophage [21],
and potentiates HIV activity [22]; this demonstrates that
platelets products may exert dual actions regarding HIV
infection, an example of definitely complex platelet::virus
interaction.
Further, the clearance of senescent platelet by macro-
phages and neutrophils operates via P-Selectin/PSGL-1
[23]; platelets with bound-HIV seem to use the same
pattern, which indicates that HIV uses platelets for pro-
tect itself from the immune system; however, since the
first descriptions of HIV interactions with platelets, there
has been no substantiated indication of productive repli-
cation of virus within platelets and by extend of a so-
called platelet infection with HIV [5]; there is neither
any evidence that HIV induces platelets to enhanced
apoptosis.
A considerable reduction in the incidence of severe
thrombocytopenia after the introduction of highly active
antiretroviral therapy (HAART) was found, probably
due to its ability to limit bone marrow damage induced
by uncontrolled HIV-1 replication and opportunistic
infections [24]. However, protease inhibitors or non-
nucleoside reverse-transcriptase inhibitors do not reduce
levels of the soluble platelet activation markers P-selectin
and CD40L [25]. HAART alters inflammation linked to
platelet cytokines in HIV-1-infected patients [26].
In all, HIV-1 is capable of entering platelets but out-
come of this entry is still largely unclear, as platelets are
not thought to consistently disseminate infection, nor
are their considered to be reservoirs. HIV-1 also acti-
vates infected as well as non-infected platelets and
contributes to local vascular inflammation. However,
antiretroviral therapy—if it ameliorates the platelet de-
crease in numbers—accelerates the pro-inflammatory
potential of platelets on vascular endothelium.
Platelets and Hepatitis C virus (HCV)
HCV is a positive-sense single-stranded RNA virus of
the Flaviviridae family, genus Hepacivirus. Chronic HCV
infection is associated with the development of severalextra-hepatic manifestations including thrombocytopenia
[27]. When HCV treatment consists in associating pegy-
lated interferon and ribavirin, thrombocytopenia is also
among the numerous side effects of this bitherapy, and the
condition can potentially be induced or exacerbated during
treatment [28]. It renders chronically infected patients
either ineligible for such a treatment or eligible for an
adapted course (reduced or discontinued doses), which can
potentially decrease the probability of successful HCV
treatment [27]. Some studies have shown a decreasing
trend of platelet count with increasing fibrosis and cirrho-
sis among patients with chronic liver disease. Among these
patients, the reduction in platelets is mainly caused by
platelet destruction from splenic pooling, because of portal
hypertension. Indirect evidence supports also the hypoth-
esis of bone marrow suppression by HCV, partly mediated
by a reduction of thrombopoetin (TPO) production due to
liver cirrhosis and/or fibrosis [29-31]. However, in HCV in-
fection, the virus itself or other mechanisms can also lead
to low platelet counts [32-34]. Thrombocytopenia in HCV
infection is complex and multiple mechanisms are in-
volved. Besides the central decrease of megakaryocytosis
due to TPO defects and possible direct viral suppression
[35,36], increased peripheral immune-mediated destruction
of platelets and hypersplenism may lead also to increased
splenic platelet sequestration [29,37].
To explain the immune destruction of platelets, sev-
eral hypotheses have been put forward: the HCV binding
to platelet membrane (with consequent binding of anti-
HCV antibody and phagocytosis of platelets), and an
impairment of host immune system triggering the pro-
duction of autoantibodies against platelet glycoproteins
are the two most frequently postulated immune mecha-
nisms explaining increased peripheral platelet destruction
in HCV-infected cases [35,38-40]. Thrombocytopenia is
now considered as a marker of HCV infection, which in-
volves that all patients with low platelet count must be
screened for the virus, especially in regions with high rates
of infection [41,42].
In case of thrombocytopenia, the ultimate aim in
HVC-positive patients is not to normalize the platelet
counts [43], but to attain and maintain a safe hemostatic
level that avoids hemorrhage on one hand and throm-
bosis on the other. Administration of Elthrombopag, a
synthetic agonist of the TPO receptor that activates
JAK2/STAT signaling pathways and induces increased
proliferation and differentiation of human bone marrow
progenitor cells into MKs and thus increased platelet
production [44,45], has been proposed to meet this pur-
pose [46,47].
Platelets and dengue virus
Dengue is a tropical infectious disease caused by the
single positive-stranded RNA virus of the Flaviviridae
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threat in temperate climates where permissive mosqui-
toes are present [48,49]. It is always feared because of
the possible severity of clinical symptoms (1% of cases)
and because of the possibility that diseases evolves to a
hemorrhagic form, with considerable drop in platelet
count [50]. Even non-hemorrhagic dengue infections
present with decreased numbers of circulating platelets
[51]. In the recent past years, the role of platelets in
regulating endothelial integrity and dengue-associated
plasma leakage has gained increased interest [52-57].
Studies using platelet aggregometry showed reduced ag-
gregation in dengue patients [58-60], but because the re-
liability of aggregometry is compromised in conditions
with thrombocytopenia, these findings need to be inter-
preted with caution. There are, meanwhile, other platelet
function alterations that are associated with plasma leak-
age [61]: dengue infection is generally associated with
platelet activation with an increased expression of the
activated fibrinogen receptor (αIIbβ3), the lysosomal
marker CD63 and the alpha-granule marker CD62P
(P-selectin). Indeed, Hottz et al. have reported a con-
sistent increase of CD62P expression in isolated platelets
from dengue patients [57]. The concentration of serotonin
is increased in platelets of patients, perhaps as a conse-
quence of platelet destruction or due to some upregula-
tion of serotonin transporter (SERT), as it has been
described to occur in association with activation of the
αIIbβ3 integrin [62]. Upon maximal platelet activation by
TRAP (Thrombin Receptor Activating Peptide), platelet
function defects were observed with a significantly re-
duced maximal activated αIIbβ3 and CD63 expression and
reduced platelet-monocyte and platelet-neutrophil com-
plexes. Dengue infection stimulates platelets to produce
pro-IL-1β, possibly de novo; mature IL-1β increases the
production of PMPs, which themselves augment vascular
permeability [56]. A molecular pattern for the binding of
Dengue Virus on Platelets is DC-SIGN [63], the very same
receptor that characterizes DV binding on the primary
target i.e. dendritic cells [64]. This DV::platelet ligation
enhances Phosphatidylserine expression by platelets—a
signature of apoptosis—and a call for phagocytosis by
macrophages [65].
Regarding platelets, dengue infection is not exempt of
unexpected and somewhat paradoxical data: whereas
Tsai et al. [66] and Onlamoon et al. [67] found an in-
crease in platelet-leukocyte aggregates during dengue in-
fection in humans and macaques, respectively, the
circulating level of monocytes and polymorphonuclear
cells was decreased. Further, at the febrile phase, inter-
feron gamma-induced protein 10 (IP-10) is fairly de-
tected in dengue patients with and without warning
signs, and during defervescence as well; however, MIP-
1β (Macrophage Inflammatory Protein-1 β) and MCP-1(Monocyte chemotactic protein-1) are elevated only in
patients with warning signs at this phase and G-CSF
(Granulocyte colony-stimulating factor) is significant in
patients without warning signs. There are further signifi-
cant correlations between the levels of VEGF (vascular
endothelial growth factor) , RANTES (regulated on acti-
vation, normal T cell expressed and secreted) , IL-7,
IL-12, PDGF (Platelet-derived growth factor) and IL-5
with platelets; VEGF with lymphocytes and neutro-
phils; G-CSF and IP-10 with atypical lymphocytes and
various other cytokines with the liver enzymes are re-
ported [68]. In all, these data suggest complex interac-
tions between virus, platelets and leukocytes. Because
platelets and leukocytes are seminal to primary hemostasis
and further to clotting, it may be envisioned, although ex-
perimental data is lacking, that those intertwined relation-
ships are defective at a stage, allowing vessel leakage and
hemorrhage.
The situation seems worsened because dengue virus
infection is accompanied by a dampening of central
megakaryogenesis. The down-regulation of haematopoi-
esis is probably a protective mechanism of the micro-
environment that limits injury to the marrow stem/
progenitor cell compartment during the subsequent
process of elimination of infected cells [3].
Dengue fever is one of the rare infectious diseases that
necessitates platelet component (PC) transfusion; PC
transfusion is not systematic as infected individuals who
do not bleed or present early signs of bleeding must not
be transfused, even with a prophylactic perspective. PC
transfusion is however indicated and must not be de-
layed in bleeding patients; this therapy has become very
safe regarding the risk of transmission of other infec-
tious agents at least in economically wealthy countries,
and the immunological risk is kept minimal in occa-
sional transfusion [69]. One must however be aware that
dengue outbreaks pose threats to the PC inventory be-
cause the needs increase considerably while the number
of healthy, non infected blood donor candidates is cor-
relatively diminished, and because additional tests must
be applied to detect viral markers (antigens and, re-
cently, viral RNA). This also poses an economical bur-
den to the public health systems.
Platelets and arenaviruses
Several members of the Arenaviridae family are etiologic
agents of viral hemorrhagic fevers (VHFs) in humans, a
syndrome characterized by fever and bleeding complica-
tions that may ultimately lead to shock and death [70].
Different experimental models shed light on the role of
platelets in VHF [50]. It was reported that mice infected
with an acute strain (Armstrong) of lymphochoriome-
ningitis virus (LCMV), a prototype representative of
Arenaviridae that was shown able to be episodically
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hemorrhagic anemia that became severe and eventually
lethal in animals depleted of platelets or lacking integrin
β3. In addition to the life-threatening hemorrhagic
anemia, platelet-depleted mice failed to mount an effi-
cient cytotoxic T lymphocyte (CTL) response and could
not clear LCMV. Remarkably, lethal hemorrhage was
less frequently associated with thrombocytopenia and in-
stead was more closely associated with platelet dysfunc-
tion mediated by high type I interferon levels [71]. These
observations confirm that platelets are necessary to pro-
tect vascular integrity and are critical mediators of viral
clearance; they also outline the generally underscored
and underappreciated relationships between primary
hemostasis, viral infection and immunosuppression.
It is noteworthy that there are important differences
between the LCMV mouse model for thrombocytopenia
in which IFN-α/β mediates the decrease in platelet num-
bers, platelet dysfunction and bleeding, and the LCMV
primate model, in which the IFN-α/β expression is
not correlated to the presence of bleeding signs
[71,72]. However, the role of type I IFN in mediating
thrombocytopenia and platelet dysfunction was further
supported by the infection of human CD34+ cells by Junin
virus, an arenavirus that causes Argentinian Haemorrhagic
Fever. In this disease, thrombopoiesis is selectively im-
paired by a decrease of pro-platelet formation, platelet re-
lease and P-selectin externalization [73]. This mechanism
is supported by the recent observation that MKs express
functional type I IFN receptors, suggesting that mega-
karyo/thrombopoiesis regulation by type I IFN is associ-
ated with a specific interaction with its receptor, and that
these cells may play a role in the antiviral defense by being
both type I IFN producers and responders [74].
Very recently, it was shown that mice profoundly
depleted of platelets (<2.5%) and infected with the
Armstrong LCMV strain developed systemic bleeding
and hemorrhagic spots in several organs along with high
viral titers, generalized splenic necrosis and increased
mortality. Interestingly, the partial depletion (15%) of
platelets was sufficient to prevent vascular damage but
not viral replication, necrotic destruction of innate and
adaptive immune splenocytes or CTL exhaustion [75].
The existence of different platelet requirements for con-
trolling vascular integrity and immune response is an
interesting novel concept, which suggests that these 2
events may be mediated by separated pathways at the
platelet level. Moreover, these data give further support
to the increasing evidence of the critical role of the
physical interaction between platelets and immune cells
to the host immune response during viral infection.
However an important issue that requires further clarifi-
cation is the molecular basis governing platelet inter-
action with immune cells in VHF.The role of platelets in the immunosuppression occur-
ring after infection by clone-13 of LMCV, a chronic,
persistent strain, and treatment with TPO was also in-
vestigated [76]. Despite an increase in the number of
platelets, no differences were seen in LCMV viral titers,
indicating that other mechanisms mediate the deficient
immune response seen in LCMV clone-13 infection.
Interestingly the authors hypothesized that the selective
inactivation of IFN-α/β signaling in MKs without alter-
ing their important antiviral activity in immune and
stromal cells was found able to completely overcome the
thrombocytopenia induced by infection with LCMV
clone-13.
Among the different pathogenic mechanisms that ac-
count for the bleeding complications of VHF induced by
arenaviruses, the presence of a platelet inhibitor has
been reported in the serum of Lassa [77] and Junin virus
infected-patients. This factor was not neutralized by
plasma containing high titers of protective antibodies
against Junin virus [78], suggesting that it is not a virus-
derived molecule. Although this inhibitor has not yet
been characterized, thrombomodulin could be a poten-
tial candidate. Indeed, thrombomodulin was shown to
bind thrombin and block the ability of thrombin to acti-
vate platelets. Moreover, peripheral blood mononuclear
cells (PBMC) exposed to a pathogenic Lassa virus in-
crease expression of thrombomodulin mRNA. This pat-
tern was observed also at the protein level in PBMC and
dendritic cells for both soluble and membrane-bound
thrombomodulin [50]. Thus, it is conceivable that the
platelet aggregation inhibitor found in Lassa or Junin
virus-infected patients is thrombomodulin, awaiting for
laboratory confirmation.
Collectively, these data indicate that homeostatic ab-
normalities together with the antiviral immune response
and high levels of viremia observed in arenavirus infec-
tion are partly regulated by platelet-virus interactions.
Conclusion
In the light of the preceding considerations, the relation-
ship between platelets and viruses appears to be very
complex and heterogeneous. The commonest feature is
probably the decrease of platelet count during viral in-
fection, with sometimes threatening levels and bleeding.
Two other common features are a profound disturbance
of the coagulation process at large (primary hemostasis,
clotting and fibrinolysis) and a sustained inflammation,
some platelet factors intervening in both hemostasis and
inflammation; a special link between these two events is
very likely during viral infection but not yet fully under-
stood. The functional properties of platelets are pro-
foundly altered during viral infection and in particular
their capacity to control the leukocyte containment
within circulation or emigration to tissues; viral infections
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companied by an altered vascular integrity, allowing leak-
age. The role of platelets as exerting virostatic effects
would also need to be addressed; although it seems rather
limited or at least over-helmed by the global inflammatory
environment, the fact that platelets are induced to massive
death as consequences of direct attacks of viruses or virus-
infected cells must be taken into consideration. Finally, a
better understanding of the interplay between platelets and
viruses would certainly help correcting the platelet defects
that are commonly observed and that may be severe, with
no treatment identified so far; platelet component transfu-
sions may be needed but, even though, with imprecise and
non consensual recommendations for prescriptions and
use. In aggregate, roles of viral platelets in viral infection
are dominated by pathologic inflammation with evident
but not exclusive consequences in hemostasis. Further re-
search in platelet mediated-immunity during viral infection
would be helpful, both from a conceptual point of view
due to the variety of current pathophysiological situations
and the likely severity of certain clinical pictures, especially
when hemorrhagic symptoms are present.
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